The present invention relates to compounds according to the general formula (I)

wherein X is selected from the group consisting of

$$\left(\begin{array}{c} \left(\begin{array}{c} \left(\begin{array}{c} \left(1\right) \\ \left(1\right) \end{array}\right) \end{array}\right)_{p} \right)$$
; $\left(\begin{array}{c} \left(\begin{array}{c} \left(1\right) \\ \left(1\right) \end{array}\right) \end{array}\right)_{p} \right)$;

wherein n and p are independently 0, 1, 2, or 3, provided that n + p is at least 1;

and unsubstituted and at least monosubstituted C_1 - C_{10} -alkylene-Y, C_{1112} - C_{10} -alkenylene-Y, C_3 - C_{10} -cycloalkylene-Y and C_3 - C_{10} -cycloalkenylene-Y; and

 $R^{1},\,A,\,B,\,Q,\,T,\,\underline{Y},\,\underline{E}$ and W and X have the meanings given in the description.

These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.